Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.
True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.
True Health will pay $37.1 million to acquire substantially all the assets of Health Diagnostic Laboratory, which is currently in Chapter 11 reorganization.
True Health seeks to acquire substantially all the assets of Health Diagnostics Laboratory, which filed for Chapter 11 bankruptcy protection in June.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.